HC Wainwright Comments on Bausch + Lomb Q1 Earnings

Bausch + Lomb Corporation (NYSE:BLCO) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Bausch + Lomb in a report released on Monday, February 23rd. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of $0.14 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.74 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.27 EPS and FY2026 earnings at $0.78 EPS.

A number of other brokerages have also commented on BLCO. Barclays increased their price objective on shares of Bausch + Lomb from $17.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Stifel Nicolaus set a $16.00 target price on shares of Bausch + Lomb in a research report on Thursday, February 19th. Raymond James Financial reissued an “outperform” rating and issued a $19.00 price target (up from $18.00) on shares of Bausch + Lomb in a report on Thursday, October 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $18.00 price objective on shares of Bausch + Lomb in a report on Thursday, February 19th. Finally, Citigroup increased their price objective on Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $18.25.

Bausch + Lomb Price Performance

Shares of BLCO stock opened at $18.58 on Tuesday. Bausch + Lomb has a 52 week low of $10.45 and a 52 week high of $18.92. The stock has a market capitalization of $6.58 billion, a PE ratio of -18.21, a PEG ratio of 0.76 and a beta of 0.61. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.04 and a current ratio of 1.55. The stock’s fifty day moving average is $17.15 and its 200-day moving average is $15.95.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.38 billion. Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The company’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.25 earnings per share.

Institutional Trading of Bausch + Lomb

Hedge funds have recently modified their holdings of the company. Oaktree Capital Management LP acquired a new position in Bausch + Lomb in the second quarter valued at about $32,801,000. Handelsbanken Fonder AB bought a new position in shares of Bausch + Lomb during the 2nd quarter valued at about $202,000. Goldentree Asset Management LP lifted its holdings in shares of Bausch + Lomb by 14.9% during the 2nd quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock valued at $33,524,000 after purchasing an additional 334,916 shares in the last quarter. Kazazian Asset Management LLC acquired a new position in shares of Bausch + Lomb in the 2nd quarter valued at approximately $722,000. Finally, Fountainhead AM LLC bought a new stake in Bausch + Lomb during the 2nd quarter worth approximately $193,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.